Dai ichi Life Insurance Company Ltd Sells 6,000 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Dai ichi Life Insurance Company Ltd decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 63.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,430 shares of the medical research company’s stock after selling 6,000 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Charles River Laboratories International were worth $709,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of CRL. APG Asset Management US Inc. bought a new stake in Charles River Laboratories International during the 4th quarter valued at $2,321,000. Norges Bank bought a new stake in shares of Charles River Laboratories International in the 4th quarter valued at about $101,319,000. Boston Trust Walden Corp boosted its position in shares of Charles River Laboratories International by 2.8% in the 2nd quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock worth $41,381,000 after purchasing an additional 5,375 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of Charles River Laboratories International by 5.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 56,840 shares of the medical research company’s stock valued at $15,401,000 after acquiring an additional 2,739 shares in the last quarter. Finally, Global Assets Advisory LLC acquired a new stake in Charles River Laboratories International during the 1st quarter worth about $8,301,000. Institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the topic of a number of recent analyst reports. The Goldman Sachs Group lowered their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Barclays dropped their price objective on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Robert W. Baird lowered Charles River Laboratories International from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $239.00 to $191.00 in a research report on Thursday, August 8th. JPMorgan Chase & Co. lowered Charles River Laboratories International from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $270.00 to $205.00 in a research note on Thursday, August 8th. Finally, Baird R W cut shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. Ten research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and an average price target of $231.00.

Charles River Laboratories International Stock Up 2.6 %

CRL stock opened at $203.73 on Tuesday. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average price is $209.42 and its 200 day moving average price is $225.08. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The company has a market cap of $10.49 billion, a P/E ratio of 23.97, a P/E/G ratio of 3.89 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.03 billion. On average, research analysts expect that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its board has approved a share repurchase program on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 9.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).